Suggested remit: To appraise the clinical and cost effectiveness of aficamten within its marketing authorisation for treating symptomatic obstructive hypertrophic cardiomyopathy.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- Cost Comparison Standard
- ID number:
- 6575
Provisional Schedule
- Expected publication:
- 29 July 2026
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email TACommC@nice.org.uk
- External Assessment Group:
- Peninsula Technology Assessment Group (PenTAG), University of Exeter
Stakeholders
- Companies sponsors
- Cytokinetics UK (aficamten)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Cardiomyopathy UK
- Professional groups
- British Cardiovascular Society
- Royal College of Physicians
- Society for Cardiac Science and Technology
- Associated public health groups
- None
- Comparator companies
- Bristol Myers Squibb (mavacamten)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- None
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 February 2026 | Invitation to participate |
| 31 October 2025 - 02 December 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6575 |
| 31 October 2025 | In progress. Scoping commencing |
| 02 October 2025 | Note - Note added to the project documents |
| 15 April 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual